


wherein
R^1 is a cyclohexyl optionally substituted by a C_{1-6} alkoxy optionally substituted by a hydroxy,
R^2 is a C_{1-6} alkyl, and
A is a phenylene optionally substituted by a halogen atom.

14. The compound according to claim 1, wherein the compound comprises 4-[trans-4-(2-Hydroxy-2-methylpropoxy)cyclohexyl]-6-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-7-propylpyrazolo[1,5-a]pyrimidin-5(4H)-one or a salt thereof.

15. The compound according to claim 1, wherein the compound comprises 6-{[3-Fluoro-2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-4-[trans-4-(2-hydroxy-1,2-dimethylpropoxy)cyclohexyl]-7-propyl[1,2,4]triazolo[1,5-a]pyrimidin-5(4H)-one or a salt thereof.

~~16. A prodrug of the compound according to claim 1.~~

~~17~~16. A medicament comprising the compound according to claim 1 ~~or a prodrug thereof~~.

~~18~~17. The medicament according to claim ~~17~~16 having an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity.

~~19~~18. The medicament according to claim ~~17~~16 which is an agent for

the prophylaxis or treatment of a circulatory disease.

~~20~~19. The medicament according to claim ~~17~~ 16 which is an agent for the prophylaxis or treatment of hypertension, a cardiac disease, arteriosclerosis, a renal disease, an ophthalmic disease, a liver disease, cerebral apoplexy, hyperlipidemia, obesity, and/or diabetes.

~~21. A method of inhibiting an angiotensin II receptor and activating a peroxisome proliferator-activated receptor γ in a mammal, comprising administering the compound according to claim 1 or a prodrug thereof to the mammal.~~

~~22. A method for the prophylaxis or treatment of a circulatory disease in a mammal, comprising administering the compound according to claim 1 or a prodrug thereof to the mammal.~~

~~23. A method for the prophylaxis or treatment of hypertension, a cardiac disease, arteriosclerosis, a renal disease, an ophthalmic disease, a liver disease, cerebral apoplexy, hyperlipidemia, obesity and/or diabetes in a mammal, comprising administering the compound according to claim 1 or a prodrug thereof to the mammal.~~

~~24~~20. Use of the compound according to claim 1 ~~or a prodrug thereof~~ for the production of a medicament having a angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity.

~~25~~21. Use of the compound according to claim 1 ~~or a prodrug thereof~~ for the production of an agent for the prophylaxis or treatment of a circulatory disease.

~~26~~22. Use of the compound according to claim 1 ~~or a prodrug thereof~~ for the production of an agent for the prophylaxis or treatment of hypertension, a cardiac disease, arteriosclerosis, a renal disease, an ophthalmic disease, a liver disease, cerebral apoplexy, hyperlipidemia, obesity and/or diabetes

treatment of hypertension, a cardiac disease, arteriosclerosis, a renal disease, an ophthalmic disease, a liver disease, cerebral apoplexy, hyperlipidemia, obesity and/or diabetes.